Condition: Opioid Use Disorder · Sponsor: Boston Medical Center
This study aims to improve retention in buprenorphine treatment, a medication used for opioid use disorder, through the use of a smartphone-delivered recovery support intervention. The intervention involves an Embodied Conversational Agent (ECA), a virtual, animated computer agent designed to simulate natural face-to-face conversations. ECAs have been shown to help individuals manage their healthcare in other settings, and this study seeks to evaluate their potential in supporting patients on medication for opioid use disorder (MOUD).
This description comes directly from the study's public registry record.
Karsten Lunze, MD MPH DrPH · 617 414 6933 · karsten.lunze@bmc.org
Samantha Blakemore, MPH · 617-383-9226 · samantha.blakemore@bmc.org
Always discuss trial participation with your own doctor first.
| Office-Based Addiction Treatment (OBAT) Clinic, BMC | Boston, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06732596